Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Director Noah G. Levy acquired 69,087 shares of the business’s stock in a transaction on Tuesday, November 24th. The shares were purchased at an average price of $3.65 per share, with a total value of $252,167.55. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
NASDAQ:MACK opened at $3.83 on Monday. Merrimack Pharmaceuticals, Inc. has a 12 month low of $1.49 and a 12 month high of $4.75. The stock has a 50 day moving average of $3.84 and a two-hundred day moving average of $3.66.
Large investors have recently bought and sold shares of the business. Western Standard LLC increased its stake in Merrimack Pharmaceuticals by 3.1% during the 2nd quarter. Western Standard LLC now owns 869,354 shares of the biopharmaceutical company’s stock worth $2,895,000 after buying an additional 26,441 shares in the last quarter. Bronte Capital Management Pty Ltd. purchased a new stake in shares of Merrimack Pharmaceuticals in the third quarter valued at approximately $2,052,000. LVW Advisors LLC purchased a new stake in shares of Merrimack Pharmaceuticals in the third quarter valued at approximately $80,000. Nantahala Capital Management LLC grew its position in shares of Merrimack Pharmaceuticals by 0.6% in the third quarter. Nantahala Capital Management LLC now owns 751,943 shares of the biopharmaceutical company’s stock valued at $3,008,000 after purchasing an additional 4,308 shares in the last quarter. Finally, Private Advisor Group LLC purchased a new stake in shares of Merrimack Pharmaceuticals in the second quarter valued at approximately $25,000. Institutional investors own 46.05% of the company’s stock.
Merrimack Pharmaceuticals Company Profile
Merrimack Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5.
Further Reading: Insider Trading
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.